OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:22 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease

NCT05517447 · Immunovant Sciences GmbH · PHASE3 · terminated · last registry update 2026-04-29 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“The feeder studies (i.e., IMVT-1401-3201 and 3202) for study IMVT-1401-3203 failed to achieve their pre-defined primary efficacy outcomes. Accordingly, there was a change to the benefit-risk balance. No new safety findings were observed.”–Registry record, Immunovant Sciences GmbH

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against FCGRT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision